Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc is positioning itself favorably in the biopharmaceutical sector by significantly increasing its R&D expenditures, which rose 23% to $21.0 million, indicating a strong commitment to advancing its innovative RNA editing technologies. The reduction in operating expenses by 13% to $20.3 million highlights the company’s strategic efforts to manage costs while still driving their research initiatives, thereby enhancing cash runway into 2H27. Additionally, the recognition of $1.1 million in collaborative revenue from a partnership with Novo Nordisk underlines the potential for further growth and financial stability as the company continues to explore new therapeutic opportunities.

Bears say

Korro Bio Inc faces significant challenges that contribute to a negative outlook on its stock. The potential for inferior pharmacologic profiles compared to existing therapies poses a risk to the company’s marketing and return on investment capabilities, particularly if clinical trials do not meet expectations. Additionally, there are concerns regarding the necessity for capital raises, which could dilute shares and adversely affect the company's ability to execute its development plans, compounded by the inherent volatility of the biotech sector.

KRRO has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 7 analysts, KRRO has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.